Oncobiologics Appoints Dr. Todd C. Brady to its Board of Directors
Cranbury, NJ -- October 7, 2014 – Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors.
Pankaj Mohan, Ph.D., Founder and CEO of Oncobiologics, stated, “We are delighted to welcome Dr. Brady to our Board. Given his experience as a venture capital investor, and his recent leadership of Aldeyra through its initial public offering, we believe Todd’s insight will be essential as Oncobiologics navigates our next stage of development.”
Dr. Brady remarked, “I am pleased to join the Oncobiologics board during this time of rapid growth. The company has achieved excellent technical progress since its founding just three years ago, and I look forward to leveraging my experience to help guide the company through its next phase.”
Dr. Brady joined Aldeyra as CEO, President and Director in 2011, where he was instrumental in leading the company through its initial public offering on NASDAQ. Prior to Aldeyra, he was an entrepreneur-in-residence and principal at Domain Associates, where he led institutional financing in numerous biotechnology companies from 2004 to 2013. Prior to joining Domain, Dr. Brady was a co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma). Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School, and an A.B. from Dartmouth College.
